# A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia

Study · id `cardio:ct-nct06834932` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06834932](<https://clinicaltrials.gov/study/NCT06834932>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06834932

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 432 participants.

## Technical summary

Registry record NCT06834932. Randomized; triple masking; primary purpose treatment. Start 2024-12-06 (actual); primary completion 2027-02-22 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 432 participants (enrolled count; ClinicalTrials.gov record NCT06834932, source copy `cardio:ctgov-nct06834932-2026-11-13`, retrieved 2026-11-18)
- Started: 2024-12-06 (actual) (ClinicalTrials.gov record NCT06834932, source copy `cardio:ctgov-nct06834932-2026-11-13`, retrieved 2026-11-18)
- Primary completion: 2027-02-22 (anticipated) (ClinicalTrials.gov record NCT06834932, source copy `cardio:ctgov-nct06834932-2026-11-13`, retrieved 2026-11-18)
- Completion: 2027-02-22 (anticipated) (ClinicalTrials.gov record NCT06834932, source copy `cardio:ctgov-nct06834932-2026-11-13`, retrieved 2026-11-18)
- Countries: China; Hong Kong SAR China (ClinicalTrials.gov record NCT06834932, source copy `cardio:ctgov-nct06834932-2026-11-13`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06834932-2026-11-13`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia
- Condition: Dyslipidaemia
- Intervention (Drug): Placebo
- Intervention (Drug): Rosuvastatin Dose 1
- Intervention (Drug): Rosuvastatin dose 2
- Intervention (Drug): AZD0780
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 2f89cb0fadc29e0472110b7109fea40ec24d8679376e7f1fae60dac7749393e3
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
